Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis
暂无分享,去创建一个
[1] Alan J. Miller,et al. Subset Selection in Regression , 1991 .
[2] Alan J. Miller. Subset Selection in Regression , 1992 .
[3] H. Keselman,et al. Backward, forward and stepwise automated subset selection algorithms: Frequency of obtaining authentic and noise variables , 1992 .
[4] James E. Bennett,et al. The Bayesian modeling of covariates for population pharmacokinetic models , 1996 .
[5] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[6] E W Steyerberg,et al. Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis. , 1999, Journal of clinical epidemiology.
[7] E N Jonsson,et al. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.
[8] Lewis B. Sheiner,et al. Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients , 1999, Antimicrobial Agents and Chemotherapy.
[9] N. Holford,et al. The pharmacokinetics of theophylline in premature neonates during the first few days after birth. , 1999, Therapeutic drug monitoring.
[10] G. Anderson,et al. Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy , 2000, Epilepsy Research.
[11] H. Zhou,et al. Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects. , 2000, British journal of clinical pharmacology.
[12] J. Habbema,et al. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. , 2000, Statistics in medicine.
[13] L. Grochow,et al. Population pharmacokinetic model for topotecan derived from phase I clinical trials. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] I. Trocóniz,et al. Pharmacokinetic-Pharmacodynamic Modelling of the Antipyretic Effect of Two Oral Formulations of Ibuprofen , 2000, Clinical pharmacokinetics.
[15] I. Court-Fortune,et al. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. , 2000, British journal of clinical pharmacology.
[16] M. Tempero,et al. Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil , 2000, Cancer Chemotherapy and Pharmacology.
[17] D. Ouellet,et al. Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer , 2000, Cancer Chemotherapy and Pharmacology.
[18] Tomohiro Sudo,et al. Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study , 2001, Cancer Chemotherapy and Pharmacology.
[19] Frank E. Harrell,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .
[20] Willi Sauerbrei,et al. Variable Selection and Shrinkage: Comparison of Some Approaches , 2001 .
[21] Peter L. Bonate,et al. The Effect of Collinearity on Parameter Estimates in Nonlinear Mixed Effect Models , 1999, Pharmaceutical Research.
[22] Mats O. Karlsson,et al. Automated Covariate Model Building Within NONMEM , 1998, Pharmaceutical Research.
[23] M. Hutmacher,et al. Efficient Screening of Covariates in Population Models Using Wald's Approximation to the Likelihood Ratio Test , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[24] Mats O. Karlsson,et al. Assessment of Actual Significance Levels for Covariate Effects in NONMEM , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[25] Donald R. Stanski,et al. Evaluation of population (NONMEM) pharmacokinetic parameter estimates , 1990, Journal of Pharmacokinetics and Biopharmaceutics.
[26] Lewis B. Sheiner,et al. Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.
[27] M. O. Karlsson,et al. The importance of modeling interoccasion variability in population pharmacokinetic analyses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[28] D. Stanski,et al. A three-step approach combining bayesian regression and NONMEM population analysis: Application to midazolam , 1991, Journal of Pharmacokinetics and Biopharmaceutics.
[29] Alain Durand,et al. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: Application to pefloxacin in intensive care unit patients , 1992, Journal of Pharmacokinetics and Biopharmaceutics.